Sanjivani Paranteral Limited operates as a pharmaceutical company in India. The company manufactures pharmaceutical products in the form of oral solids, small volume parenteral, and sterile powder formulations for various therapeutic areas, including central nervous system, cardiovascular system, antibiotics, gastroenterological, anti-diabetics, and anti-allergic. It also offers soft gels, such as multivitamins; topicals comprising corticosteroids, antiseptics, NSAIDs, and anti-bacterial; nasal sprays; liquid and dry powder injections covering antibiotics, anti-emetic, NSAID and analgesic, antimalarial, and proton pump inhibitor and H2 receptor antagonist; capsules and tablets, including antibiotic, antifungal, anticonvulsant, multivitamins, and NSAID and analgesic; dry syrups; and ear/eye drops. In addition, the company exports its products. Sanjivani Paranteral Limited was incorporated in 1994 and is headquartered in Mumbai, India.
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
The Information Technology sector gained 3.8% while the market remained flat over the last week. The past year hasn't been profitable, with the market dropping 4.1%. Looking forward, earnings are forecast to grow by 16% annually. Market details ›